Tracking a leukemia Drug's Real-Life performance
NCT ID NCT07288515
Summary
This study aims to understand how well the drug acalabrutinib works for chronic lymphocytic leukemia (CLL) in everyday medical practice in Belarus. It will follow 50 adult patients who have just started taking the drug for about two years, collecting information on how long they stay on it and why they might stop. The goal is to gather real-world data on the drug's effectiveness and safety outside of a controlled clinical trial setting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGMinsk, Belarus
Conditions
Explore the condition pages connected to this study.